Modern multimodality approach to hepatic colorectal metastases: solutions and controversies.
about
Chemotherapy for downstaging unresectable liver metastases from colorectal cancerPhase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability statusMulti-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer.Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treatedAn update on chemotherapy of colorectal liver metastasesBiological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM): Looking Beyond the Tumor Margin.Percutaneous cryosurgery for the treatment of hepatic colorectal metastases.Accomplishments in 2008 in the management of curable metastatic colorectal cancer.Current treatment for colorectal liver metastasesLiver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches.Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis.Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy.A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of survival after radioembolization for metastatic colorectal cancer.Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation.Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes.Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy.Influence of zinc and zinc chelator on HT-29 colorectal cell line.Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis.Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastasesSignificant Shrinkage of Multifocal Liver Metastases and Long-Term Survival in a Patient With Rectal Cancer, After Trans-Arterial Chemoembolization (TACE): A Case Report.Accomplishments in 2007 in the management of curable metastatic colorectal cancer.Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases.
P2860
Q24234615-E2EEB409-2BFE-465C-8BC5-0A87B85DA460Q33388487-4ACE486F-85CC-44CD-AEE6-D8140ADC60B1Q33390290-DDD82341-ED5F-46F0-A183-475EDFD7C042Q33392260-00C1C4A7-BBAF-4E64-ADD5-985F3AC32E1BQ33630882-65C09C94-FC42-4E57-BEF1-DD2DCBB7491FQ34059726-1D8D7D22-DAD2-4B6F-AB80-2BB4FF905DFAQ34618747-B241B1E2-8862-4614-AB27-E75D000DF243Q35040601-65CFE6E0-9D8B-42A7-AE59-3148727B9AA4Q35653578-C985A46A-682F-48C6-B70B-C6AE4347DF69Q36653705-630575E8-3D24-4A7A-9419-1295B887FAACQ37220701-375AE250-3D7A-4A0F-9297-D3201957A8D9Q37468824-2337BD1A-5FF6-448D-9878-F728E9714CFEQ37951004-4DD0DFA7-99CA-486A-9DCD-7CA341E87FACQ37951604-4B07D81F-8615-4E82-94A2-2B2C335FADC9Q38024277-ED0CACB2-0A18-4A78-8C55-91F56A2587DCQ38135754-E67558D3-3D0A-4F55-BFF3-9BD87A598D5CQ38169587-4A5798E4-9385-4D05-BA17-192032727A42Q38246201-3016967F-4AA5-4F9D-B07B-2D583291E25EQ38908325-E4277065-C01B-46FE-A33F-BF9F49A8112EQ38931957-319C0EFA-2576-4A34-9C0E-F4E954DF1331Q39349646-0D401D47-BD29-4BC0-A972-E756A5905572Q39642468-05CE2E94-3F65-44DB-ADC9-E6ED4B4C65F2Q40036078-4DB03698-CC5A-4703-9B3D-87B1D97FCF17Q42003363-E5CFA031-5773-4DB8-A5ED-1360AA4ED8F4Q42067592-D1E1BD3B-FB2E-4A13-8557-F96DBD194798Q42129868-448251D1-8AF0-44D6-AA65-12D410DF8125Q50066860-49902727-5741-41B2-AA53-C85D9546D679
P2860
Modern multimodality approach to hepatic colorectal metastases: solutions and controversies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Modern multimodality approach ...... : solutions and controversies.
@en
type
label
Modern multimodality approach ...... : solutions and controversies.
@en
prefLabel
Modern multimodality approach ...... : solutions and controversies.
@en
P2093
P1433
P1476
Modern multimodality approach ...... : solutions and controversies.
@en
P2093
Karen G Chee
Nicholas J Petrelli
Vijay P Khatri
P356
10.1016/J.SURONC.2007.05.001
P577
2007-05-29T00:00:00Z